For serious conditions with high unmet need, earlier access to promising treatments can be worth the risk of greater uncertainty. But achieving this balance demands trust.

New paper, developed with input from diverse stakeholders, outlines policy options to strengthen the FDA pathway.

A New Yorker article argues that we are in "the gilded age of medicine." So what does that mean for U.S. health care? Dr. Dhruv Khullar, associate professor of health and economics at Weill Cornell Me...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

This interactive tool provides up-to-date information on U.S. health spending by federal and local governments, private companies, and individuals. It was developed by KFF using data from the National...

The Democratic Party needs to rethink what it means to be the party of institutions.

Middlemen negotiate prescription costs at thousands of different price points, depending on your insurance plan.

ALT: a cartoon character wearing a hoodie is laughing in front of a fire background .

Between RFK Jr. and Vivek Ramaswamy, the incoming Trump administration has widely divergent views on regulating the drug industry.

<p>In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting. </p>

Nonprofit hospitals are behaving in ways that seem to focus more on dollars than patients.

<p>OTP Director Nicole Verdun acknowledged the agency may need help to determine how to ensure 15 years of patient follow-up is completed despite physician retirements, company closures and other issu...

<p>The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Red...